Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402612 | 0.80 | PPARD (0.43) | KCNH2SLC6A4SLC6A3HTR2AAR | |
| SCHEMBL12096582 | 0.79 | AR (0.54) | KCNH2SLC6A4SLC6A3HTR2AAR | |
| SCHEMBL2399580 | 0.77 | SIGMAR1 (0.41) | KCNH2SLC6A4SLC6A3HTR2AAR | |
| SCHEMBL3171174 | 0.76 | KIF11 (0.37) | ARESRRAMRGPRX4 | |
| SCHEMBL3432663 | 0.74 | MRGPRX4 (0.45) | ARESRRAMRGPRX4 | |
| SCHEMBL12096571 | 0.73 | AR (0.45) | KCNH2SLC6A4SLC6A3HTR2AAR | |
| SCHEMBL2401961 | 0.73 | MGLL (0.35) | KCNH2SLC6A4SLC6A3HTR2A | |
| SCHEMBL12096613 | 0.70 | PTGDR (0.42) | SLC6A4PPARAPPARDSIGMAR1HRH1 | |
| SCHEMBL12096575 | 0.70 | PTGDR (0.42) | SLC6A4PPARAPPARDSIGMAR1HRH1 | |
| SCHEMBL12096570 | 0.70 | PTGDR (0.42) | SLC6A4PPARAPPARDSIGMAR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373162-B1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-8168681-B2 | Amidoacetonitrile compounds and pesticidal composition thereof | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NAAA, PTMS, NIT2 | KCNH2 3421/4885SLC6A4 4527/4885SLC6A3 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.